Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by ledzep4uon Aug 15, 2019 10:39am
96 Views
Post# 30031489

Good News...Last Quarter Under Bruce

Good News...Last Quarter Under BruceWhile I was a big fan of Bruce and he made me very rich, he was not the CEO to take this company to the next global expansion and revenue level. Bruce was a big spender, grower of facilities and loved to buy companies (really overpaid for Hiku) . His expenditures were out of control and not focused on revenue growth.

For revenue to come $20 million under the street's forecast and lower than last quarter, is simply unacceptable. I believe the next CEO will be cost conscious and revenue driven (the anti-Bruce). The Board, controlled by CB, will ensure that the next CEO is very focused on getting expenses under control (stock options/salaries/benefits/facility expansions etc.) and ensuring company turns its focus to revenue generation. They already have a new CFO in Mike Lee from CB so the trend to profitability has started. 

As I've posted, Q2 numbers should be very good, well over $100 million in revenue. The have $93 million in finished goods which is product ready to go out the door. They would have increased their medical clients substantially thanks to CannTrust which have higher margins and their costs would have started to be under control. 

GLTA
Bullboard Posts